Разработка современных противооспенных вакцин


Цитировать

Полный текст

Аннотация

Описана хронология развития вакцинопрофилактики оспы и показана высокая актуальность разработки современных безопасных вакцин против ортопоксвирусов. Рассмотрены 4 поколения живых противооспенных вакцин, субъединичные белковые вакцины и ДНК-вакцины. На основании анализа опубликованных данных сделан вывод о перспективности использования новейших поколений безопасных субъединичных или ДНК-вакцин против натуральной оспы для массовой первичной вакцинации с возможной последующей ревакцинацией классической живой вакциной.

Список литературы

  1. Максютов P. А., Бабкина И. H., Нестеров А. Е. и др. Создание кандидатной ДНК-вакцины против ортопоксвирусных инфекций человека // Биотехнология. - 2006. - T. 4. - С. 23-30.
  2. Максютов Р. А., Щелкунов С. Н. Оптимизация ДНК-вакцины против ортопоксвирусных инфекций человека на основе гена F8L вируса натуральной оспы // Рос. иммунол. журн. - 2010. - Т. 4. - С. 25-32.
  3. Маренникова С. С., Щелкунов С. Н. Патогенные для человека ортопоксвирусы. - М., 1998.
  4. Aldaz-Carroll L., Whitbeck J. С., Ponce de Leon M. et al. Epitope-mappin studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R // J. Virol. - 2005. - Vol. 79. - P. 6260-6271.
  5. Aldaz-Carroll L., Xiao Y., Whitbeck J. C. et al. Major neutralizing sites оf vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6 // J. Virol. - 2007. - Vol. 81. - P. 8131-8139.
  6. Berhanu A., Wilson R. L., Kirkwood-Watts D. L. Vaccination of BALB/mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge // J. Virol. - 2008. - Vol. 82. - P. 3517-3529.
  7. Blanchard T. J., Alcami A., Andrea P. et al. Modified vaccinia virus Ankarа undergoes limited replication in human cells and lacks severa immunomodulatory proteins: implications for use as a human vaccine // J. Gen. Virol. - 1998. - Vol. 79. - P. 1159-1167.
  8. Campe H., Zimmermann P., Glos K. et al. Cowpox virus transmission from pet rats to humans, Germany // Emerg. Infect. Dis. - 2009. - Vol. 15. - P. 777-780.
  9. Chung С. S., Hsiao J. С, Chang Y. S. et al. A27L protein mediates vaccini virus interaction with cell surface heparan sulfate // J. Virol. - 1998. - Vol. 72. - P. 1577-1585.
  10. Demkowicz W. E., Maa J. S., Esteban M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animal and are immunodominant in vaccinated humans // J. Virology. - 1992. - Vol. 66. - P. 386-398.
  11. Doria-Rose N. A., Haigwood N. L. DNA vaccine strategies: candidates for immune modulation and immunization regimens // Methods. - 2003. - Vol. 31. - P. 207-216.
  12. Drexler I., Heller K., Wahren B. et al. Highly attenuated modified vaccini virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells // J. Gen. Virol. - 1998. - Vol. 79. - P. 347-352.
  13. Earl P. L., Americo J. L., Wyatt L. S. et al. Immunogenicity of a highl attenuated MVA smallpox vaccine and protection against monkeypox // Nature. - 2004. - Vol. 428. - P. 182-185.
  14. Edghill-Smith Y., Bray M., Whitehouse C. A. et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge // J. Infect. Dis. - 2005. - Vol. 191. - P. 372-381.
  15. Empig C, Kenner J. R., Perret-Gentil M. et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challeng // Vaccine. - 2006. - Vol. 24. - P. 3686-3694.
  16. Fenner F., Henderson D. A., Arita I. et al. Smallpox and its eradication. - Geneva: World Health Organization, 1988.
  17. Fenner F. Risks and benefits of vaccinia vaccine use in the worldwid smallpox eradication campaign // Res. Virol. - 1989. - Vol. 140, № 5. - P. 465-466; 487-491.
  18. Fogg C, Lustig S., Whitbeck J. C. et al. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions // J. Virol. - 2004. - Vol. 78. - P. 10230-10237.
  19. Fogg С. N., Americo J. L., Lustig S. Adjuvant-enhanced antibody response to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges // Vaccine. - 2007. - Vol. 25. - P. 2787-2799.
  20. Galmiche M. С., Goenaga J., Wittek R. et al. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens // Virology. - 1999. - Vol. 254. - P. 71-80.
  21. Gurvich E. B. The age-dependent risk of postvaccination complications vaccinees with smallpox vaccine // Vaccine. - 1992. - Vol. 10, № 2. - P. 96-97.
  22. Hekker A. C., Bos J. M., Rai N. K. et al. Largescale use of freeze-dried smallpox vaccine prepared in primary ultures of rabbit kidney cells // Bull. Wld Hlth Org. - 1976. - Vol. 54, № 3. - P. 279-284.
  23. Heraud J. M., Edghill-Smith Y., Ayala V. et al. Subunit recombinant vaccine protects against monkeypox // J. Immunol. - 2006. - Vol. 177. - P. 2552-2564.
  24. Hirayama M. Smallpox vaccination in Japan // Fukumi H, editor. The vaccination theory and practice / Ed. H. Fukumi. - 1975.
  25. Hooper J. W., Custer D. M., Schmaljohn C. S. et al. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge // Virology. - 2000. - Vol. 266, № 2. - P. 329-339.
  26. Hooper J. W., Custer D. M., Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicit appropriate antibody responses in nonhuman primates // Virology. - 2003. - Vol. 306, № 1. - P. 181-195.
  27. Hooper J. W., Thompson E., Wilhelmsen C. et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox // J. Virol. - 2004. - Vol. 78, № 9. - P. 4433-4443.
  28. Hsiao J. C., Chung C. S., Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells // J. Virol. - 1999. - Vol. 73. - P. 8750-8761.
  29. Jacobs B. L., Langland J. O., Kibler К. V. et al. Vaccinia virus vaccines past, present and future // Antiviral Res. - 2009. - Vol. 84, № 1. - P. 1-13.
  30. Jones-Trower A., Garcia A., Meseda C. A. et al. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognize by vaccinia immune globulin // Virology. - 2005. - Vol. 343. - P. 128-140.
  31. Katz E., Wolffe E., Moss B. Identification of second-site mutations the enhance release and spread of vaccinia virus // J. Virol. - 2002. - Vol. 76. - P. 11637-11644.
  32. Kemper A. R., Davis M. M., Freed G. L. Expected adverse events in a mas smallpox vaccination campaign // Eff. Clin. Pract. - 2002. - Vol. 5. - P. 84-90.
  33. Lai C. F., Gong S. C., Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals // J. Virol. - 1991. - Vol. 65. - P. 5631-5635.
  34. Lane J. M., Ruben F. L., Neff J. M. et al. Complications of smallpox vaccination, 1968: results of ten statewide surveys // J. Infect. Dis. - 1970. Vol. 122. - P. 303-309.
  35. Lewis-Jones S. Zoonotic poxvirus infections in humans // Curr. Opin. Infect. Dis. - 2004. - Vol. 17. - P. 81-89.
  36. Meseda C. A., Garcia A. D., Kumar A. et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model // Virology. - 2005. - Vol. 339. - P. 164-175.
  37. Monath Т. P., Caldwell J. R., Mundt W. et al. ACAM2000 clonal Vero сеll culture vaccinia virus (New York City Board of Health strain) - a second generation smallpox vaccine for biological defence // Int. J. Infect. Dis. - 2004. - Vol. 8. - P. 31-44.
  38. Murphy F. A., Osburn В. I. Adventitious agents and smallpox vaccine in strategic national stockpile // Emerg. Infect. Dis. - 2005. - Vol. 11. - P. 1086-1089.
  39. Ninove L., Domart Y., Vervel C. et al. Cowpox virus transmission from pe rats to humans, France // Emerg. Infect. Dis. - 2009. - Vol. 15. - P. 781-784.
  40. Ober В. Т., Bruhl P., Schmidt M. et al. Immunogenicity and safety of defective vaccinia virus Lister: comparison with modified vaccinia virus Ankara // J. Virol. - 2002. - Vol. 76. - P. 7713-7723.
  41. Poland G. A., Grabenstein J. D., Neff J. M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program // Vaccine. - 2005. - Vol. 23. - P. 2078-2081.
  42. Pulford D. J., Gates A., Bridge S. H. et al. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection on BALB/c mice from a lethal intranasal poxvirus challenge // Vaccine. - 2004. - Vol. 22. - P. 3358-3366.
  43. Pütz M. M., Midgley С. M., Law M. et al. Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination // Nat. Med. - 2006. - Vol. 12. - P. 1310-1315.
  44. Ramirez J. C, Tapia E., Esteban M. Administration to mice of a monoclona antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions // J. Gen. Virol. - 2002. - Vol. 83. - P. 1059-1067.
  45. Rodriguez J. F., Paez E., Esteban M. A. 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers // J. Virol. - 1987. - Vol. 61. - P. 395-404.
  46. Rosenthal S. R., Merchlinsky M., Kleppinger C. et al. Developing new smallpox vaccines // Emerg. Infect. Dis. - 2001. - Vol. 7. - P. 920-926.
  47. Sakhatskyy P., Wang S., Chou T. H. et al. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen // Virology. - 2006. - Vol. 355. - P. 164-174.
  48. Sakhatskyy P., Wang S., Zhang C. et al. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens // Virology. - 2008. - Vol. 371. - P. 98-107.
  49. Sanderson C. M., Frischknecht F., Way M. et al. Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH induced cell-cell fusion // J. Gen. Virol. - 1998. - Vol. 79. - P. 1415-1425.
  50. Stephenson J. Monkeypox outbreak a reminder of emerging infection vulnerabilities // J.A.M.A. - 2003. - Vol. 290. - P. 23-24.
  51. Stickl H. A. Smallpox vaccination and its consequences: first experience with the highly attenuated smallpox vaccine "MVA" // Prev. Med. - 1974. - Vol. 3. - P. 97-101.
  52. Vollmar J., Arndtz N., Eckl K. M. et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine // Vaccine. - 2006. - Vol. 24. - P. 2065-2070.
  53. Weltzin R., Liu J., Pugachev K. V. et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine // Nat. Med. - 2003. - Vol. 9. - P. 1125-1130.
  54. Wolffe E. J., Isaacs S. N., Moss B. Deletion of the vaccinia virus B5R gen encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination // J. Virol. - 1993. - Vol. 67. - P. 4732-4741.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Максютов Р.А., Гаврилова Е.В., Щелкунов С.Н., Maksyutov R.A., Gavrilova E.V., Shchelkunov S.N., 2011

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах